Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
3 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenue $ 0 $ 50,000
Operating expenses:    
Research and development 1,305,000 1,606,000
General and administrative 2,801,000 3,547,000
Total operating expenses 4,106,000 5,153,000
Operating loss (4,106,000) (5,103,000)
Other income (expense):    
Interest expense (57,000) (26,000)
Interest income 174,000 55,000
Total other income 117,000 29,000
Net loss from continuing operations (3,989,000) (5,074,000)
Loss from discontinued operations   (672,000)
Net loss $ (3,989,000) $ (5,746,000)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.46) $ (4.24)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.46) (4.24)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations 0.00 (0.56)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations 0.00 (0.56)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.46) (4.80)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.46) $ (4.80)
Weighted-average common shares outstanding - basic 8,633 1,198
Weighted-average common shares outstanding - diluted 8,633 1,198